Opus Genetics is trading at $3.45 (+5.18%) in pre-market as the stock rebounds from a weak prior session despite no fresh company-specific catalysts.
- Recent downward pressure was attributed to broader biotech sector weakness and risk asset volatility, with no new FDA, earnings, or corporate announcements reported.
- The move occurs within a volatile small-cap biotech tape; with Nasdaq futures lower and sentiment soft, the rebound is viewed as overnight trading noise rather than a fundamental event.